Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular degeneration (AMD).
Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...
What Hi-Fi? on MSN
Budget Mini LED battle: who wins in this sub-£1000 showdown?
TCL C7K vs Amazon Fire TV Omni Mini-LED: which budget-friendly Mini LED TV should you buy?
Today Silas takes a look at a new custom cooled £3900 system from Cyberpower! Full review coming soon on <a ...
For an OLED TV, the Z95B is surprisingly chunky. In fact, at 2.1 inches deep, it’s thicker than most high-end LED TVs, too.
New research highlights progress in treating age-related macular degeneration, including late‑stage drug trials, gene therapy strategies, and a wireless retinal prosthesis that restored limited ...
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to ...
Regenxbio advances RGX-314 and RGX-202 pipelines for AMD and Duchenne while navigating recent FDA program setbacks. Read why RGNX stock is downgraded to buy.
Saudi Arabia froze Red Sea resort expansion to fund Project Transcendence, a $100B AI initiative. The capital shift mirrors a ...
Holiday weekends offer the opportunity to save some serious cash on upgrading your electronics, and at PCMag, we're committed ...
NZXT's new compact SFF case, the H2 Flow, is easy to build in and performs well. You may need to tweak GPU setup for best temps, but it's not daunting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results